CCDC102A: A Potential Drug Target Or Biomarker (G92922)

Target Name: CCDC102A

NCBI ID: G92922

CCDC102A

Other Name(s): MGC10992 | C102A_HUMAN | coiled-coil domain containing 102A | Coiled-coil domain-containing protein 102A | Coiled-coil domain containing 102A

CCDC102A: A Potential Drug Target Or Biomarker

CCDC102A, also known as MGC10992, is a protein that is expressed in various tissues throughout the body. It is a member of the CCDC family, which is known for its role in cell signaling and development. CCDC102A has been identified as a potential drug target or biomarker, and research is being conducted to investigate its potential uses in various diseases.

CDC102A is a transmembrane protein that is expressed in a variety of tissues, including the brain, heart, liver, and pancreas. It is characterized by a unique extracellular domain that is composed of a long alpha-helices that are involved in the protein's stability and localization to the cell surface. The protein also has a cytoplasmic tail that is involved in its stability and may contribute to its intracellular localization.

CDC102A is involved in a number of cellular processes that are important for normal development and function. It is involved in the development and maintenance of the blood-brain barrier, which is responsible for protecting the brain from harmful substances that could cause neurodegeneration. It is also involved in the regulation of cell signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and survival.

In addition to its role in cell signaling, CCDC102A is also potential drug target. The protein is known to be involved in a number of cellular processes that are important for the development and progression of various diseases, including cancer. In addition, CCDC102A is also known to be involved in the regulation of cellular processes that are important for tissue repair and regeneration, which may make it a potential target for drugs that are used to treat wound healing and other forms of tissue damage.

Research is being conducted to investigate the potential uses of CCDC102A as a drug target or biomarker. One approach is to use small molecules or antibodies to bind to the protein and then study the effects that this binding has on its function. This approach has been used to identify potential drugs that can be used to treat a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Another approach is to use CCDC102A as a biomarker to diagnose and monitor diseases. This approach has been used to identify potential biomarkers for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. By using CCDC102A as a biomarker, researchers can monitor the effectiveness of treatments and identify potential new treatments for existing diseases.

In conclusion, CCDC102A is a protein that is expressed in various tissues throughout the body and is involved in a number of cellular processes that are important for normal development and function. The protein has also been identified as a potential drug target or biomarker, and research is being conducted to investigate its potential uses in various diseases. Further studies are needed to fully understand the functions of CCDC102A and its potential as a drug target or biomarker.

Protein Name: Coiled-coil Domain Containing 102A

The "CCDC102A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC102A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets